Digital pathology leader, Deciphex, launches its Diagnostics as a service (DxaaS) in the United States

Deciphex launches its Diagnostics as a service in the United States.

DUBLIN, Ireland, September 7th, 2022— Deciphex, a leading provider of Digital Pathology software and services, announced today the launch of their Diagnexia service in the United States.

Remote expert subspecialty pathology on demand

Diagnexia virtual pathology service provides on-demand access to remote subspecialty experts for pathology consult services, on an advanced collaborative platform. This provides significant support to overworked and under-staffed pathology departments without experts available on every subspecialty.

The platform connects laboratories to an international network of subspecialty pathologists, who can provide their expertise on clinical cases, while vastly reducing turnaround times and ensuring delivery of the highest quality of patient care. Busy academic teams within hospital networks will also benefit from having extra experts available on demand to help balance workloads. Eligible retiring pathologists may join the Diagnexia network and work remotely part-time.

Global subspecialty expertise when needed

Pathology is heading for a crunch point due to increasing volumes, increasing complexity and flat to declining pathologist numbers. Pathologists are in high demand worldwide, and their number is predicted to significantly decrease over the next ten years.

Diagnexia delivers a global network of subspecialty pathology experts to ease pathology bottlenecks, accelerate diagnoses and enhance patient outcomes.

Accepted and proven internationally

Diagnexia is already a leading international service and is used by Healthcare Providers internationally including the UK’s National Health Service (NHS). Steve Blunden,  Cellular and Anatomical Pathology Operations Manager at University Hospitals Plymouth NHS Trust states: “We have recently started a partnership with Diagnexia both as a supplier of technical services to them and a user of their diagnostic service. Digital Pathology will play a key role in revolutionising this key area of healthcare provision and equip leading Pathologists with the capabilities to deliver their skills at scale.”

Donal O’Shea, Chief Executive Officer of Deciphex, adds

‍“The US launch of Diagnexia is an important milestone for the business in its ambition to use Digital Pathology and AI to provide easy access to the world’s leading pathologists. Chronic issues in Pathology such as burgeoning patient wait times, recruitment, demand for expertise and diagnostic complexity has necessitated a new approach to improving patient care.”

“Even well-resourced healthcare systems with relatively ‘High-Pathologist Density’ have a chronic lack of capacity leading to backlogs, delayed diagnosis, care, and patient outcomes. The ability to alleviate these difficulties with seamless, state of the art technology is game-changing and ultimately of huge benefit to patients, health services, and pathology labs.” he adds. 

About Deciphex‍

Deciphex is an Irish-based software & services company focused on developing digital pathology-based solutions for clinical (Diagnexia) and research (Patholytix) pathology.

Diagnexia is a remote diagnostic service that provides on-demand access to subspecialty pathologists for primary diagnostics and secondary consult services. This supports the acceleration of diagnostic turnaround times and delivery of the highest quality of patient care.

Patholytix is the industry-leading digital pathology workflow & integrated AI platform for Research Pathology. Deciphex is trusted by the leading CROs and 9 of the top 10 pharmaceutical companies for handling high-volume drug safety pathology studies, providing a complete GLP-compliant workflow with integrated AI screening capabilities.

In March 2020, Deciphex inked a key strategic partnership with the global, preclinical Contract Research Organization (CRO), Charles River Laboratories, International Inc to co-develop AI tools to accelerate drug safety assessment.

Deciphex is also a key member of BigPicture (bigpicture.eu), a major EU-funded initiative to build the world’s biggest central repository of digital pathology slides to boost the development of AI.

SOURCE: Diagnexia